BETR:CA:CNSX-BetterLife Pharma Inc (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.105

Change

-0.01 (-4.55)%

Market Cap

USD 0.01B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
DRUG:CA Bright Minds Biosciences Inc

+0.25 (+0.43%)

USD 0.38B
METX:CA METX

+0.05 (+1.25%)

USD 0.10B
GLAB:CA Gemina Laboratories Ltd

-0.08 (-10.26%)

USD 0.05B
ACOG:CA Alpha Cognition Inc.

N/A

USD 0.05B
DTC:CA Defence Therapeutics Inc

-0.03 (-4.41%)

USD 0.03B
MDMA:CA Pharmala Biotech Holdings Inc.

+0.01 (+1.69%)

USD 0.03B
DOSE:CA Rapid Dose Therapeutics Corp

N/A

USD 0.03B
PHRM:CA PharmaTher Holdings Ltd

-0.01 (-4.55%)

USD 0.02B
TELI:CA Telescope Innovations Corp.

N/A

USD 0.02B
BIOV:CA BioVaxys Technology Corp

N/A

USD 0.01B

ETFs Containing BETR:CA

XSOE WisdomTree Emerging Marke.. 1.61 % 0.32 %

-0.21 (-0.52%)

N/A
SPEM SPDR® Portfolio Emerging.. 1.15 % 0.12 %

-0.20 (-0.52%)

USD 10.23B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.00% 60% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.00% 60% D- 38% F
Trailing 12 Months  
Capital Gain 16.67% 50% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.67% 50% F 71% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.33% 44% F 38% F
Dividend Return -10.33% 44% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.12% 53% F 45% F
Risk Adjusted Return -20.21% 47% F 50% F
Market Capitalization 0.01B 69% C- 80% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.